Comparison of the cognitive effects of three immunomodulatory drugs in relapsing-remitting multiple sclerosis: a longitudinal study.

Trial Profile

Comparison of the cognitive effects of three immunomodulatory drugs in relapsing-remitting multiple sclerosis: a longitudinal study.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2015

At a glance

  • Drugs Glatiramer acetate; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2015 Last checked against ClinicalTrials.gov record.
    • 22 Mar 2012 Actual patient number is 96 according to ClinicalTrials.gov.
    • 22 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top